地特胰岛素注射液的临床效果和经济学评价研究综述

采用文献综述法,系统地分析国外已发表的地特胰岛素注射液(IDet)的临床研究和经济学评价结果,以评估地特胰岛素治疗1型和2型糖尿病患者的临床疗效和经济学价值。研究结果表明,在临床效果方面,患者从应用口服降糖药、中性鱼精蛋白锌胰岛素(NPH)或甘精胰岛素注射液(IGlar),转换使用IDet后,均有助于进一步降低患者的血糖水平。许多国家的经济学研究显示,与NPH或IGlar相比,IDet是成本节约或具有成本-效果的治疗方案。

The clinical efficacy and economic value of insulin Detemir for patients with type 1 or type 2 diabetes mellitus from published papers were analyzed through systematic literature review. The evidence showed that insulin Detemir was a predictable basal insulin with excellent glycaemic control, risk reduction of hypoglycemia and low weight gain in comparison to alternative basal insulins （NPH insulin, Insulin Glargine） in clinical studies. Pharmacoeconomics studies illustrated that insulin Detemir was a cost saving or cost effective treatment for patients with diabetes compared to NPH or insulin Glargine in many countries.